Galitzia Andrea, Barabino Luca, Murru Roberta, Caocci Giovanni, Greco Marianna, Angioni Giancarlo, Mulas Olga, Oppi Sara, Massidda Stefania, Costa Alessandro, La Nasa Giorgio
Department of Medical Sciences and Public Health, University of Cagliari, 09042 Monserrato, Italy.
Hematology and Transplant Centre, Ospedale Oncologico Armando Businco, ARNAS G. Brotzu, 09121 Cagliari, Italy.
Vaccines (Basel). 2022 Jul 21;10(7):1162. doi: 10.3390/vaccines10071162.
Patients with CLL have high rates of either severe disease or death from COVID-19 and a low response rate after COVID-19 vaccination has been reported. We conducted a single-center study with the main objective to evaluate the immunogenicity of the BNT1162b2 mRNA vaccines in 42 patients affected by CLL with the assessment of antibody response after the second and the third dose. After the second dose of vaccine, 13 patients (30%) showed an antibody response. The presence of hypogammaglobulinemia and the use of steroids or IVIG were the main factors associated with poor response. After the third dose, 5/27 (18%) patients showed an antibody response while in non-responders to the second dose, only 1 patient (4%) showed an elicitation of the immune response by the third dose, with no statistically significant difference. Our data, despite the small size of our cohort, demonstrate that patients with CLL have a low rate of effective response to the BNT162b2 vaccine. However, the effective role of a subsequent dose is still unclear, highlighting the need for alternative methods of immunization in this particularly fragile group of patients.
慢性淋巴细胞白血病（CLL）患者感染新冠病毒后发生重症或死亡的比例很高，且有报道称新冠病毒疫苗接种后的反应率较低。我们开展了一项单中心研究，主要目的是评估BNT162b2 mRNA疫苗在42例CLL患者中的免疫原性，并在接种第二剂和第三剂后评估抗体反应。接种第二剂疫苗后，13例患者（30%）出现抗体反应。低丙种球蛋白血症的存在以及使用类固醇或静脉注射免疫球蛋白是与反应不佳相关的主要因素。接种第三剂后，27例中有5例（18%）患者出现抗体反应，而在第二剂无反应者中，只有1例患者（4%）在接种第三剂后出现免疫反应激发，差异无统计学意义。尽管我们的队列规模较小，但我们的数据表明，CLL患者对BNT162b2疫苗的有效反应率较低。然而，后续剂量的有效作用仍不明确，这凸显了在这一特别脆弱的患者群体中需要采用替代免疫方法。
